Are Kurve
products safe?

Kurve’s intranasal insulin (Intrulin™) has an excellent safety record to date, documented in several published clinical studies involving over 300 patients (175 with Alzheimer’s) using the product in controlled trials. In all of these studies, the product had a good safety profile and was well tolerated. Further, long-term safety data is expected from the upcoming Kurve Intrulin™ Phase III trial in Mild Cognitive Impairment.

How is Kurve’s approach different from that of currently-prescribed drugs for Alzheimer’s disease?

Kurve is developing Alzheimer’s drugs that modify the disease itself instead of just treating the symptoms. Current treatment options — known as cholinesterase inhibitors — are drugs that can relieve some of the symptoms of Alzheimer’s disease but do not modify the disease itself. If they provide a benefit, it tends to be for short periods, approximately three to six months, before the disease progression continues.
To learn more about Kurve Therapeutics’ approach to treating CNS disorders and how it differs from current less-effective treatments, please visit our Home Page.

What conditions can Kurve’s device treat?

What differentiates us from traditional CNS disorder treatments is our ability to target a vast number of diseases through our next-generation technology. The possibilities are endless! We have studied our technology and formulations on the following disorders:

· Central nervous system disorders, including: Alzheimer’s disease, Parkinson’s disease, Lewy Body dementia, ALS, Multiple sclerosis, Mild cognitive impairment, Cognition in diabetics, Multi-system atrophy, Traumatic brain injury, PTSD, Neuropathic pain, Mood and anxiety disorders, and Autism

· Neurological disorders, including traumatic brain injury, PTSD, neuropathic pain, mood and anxiety disorders, and autism.

Visit our Clinical Trials page to learn more.

What clinical studies has Kurve been a part of?

Kurve Therapeutics’ patented medtech has been the technology of choice for more than 22 nose-to-brain clinical trials. Our technology and formulations have been studied in several disease states, including Alzheimer’s disease, Parkinson’s disease, MS, PTSD, traumatic brain injury, stem cells for glioblastoma, and more. 
Head to the Clinical Trials page to review a complete list of clinical trials that have used Kurve’s patented technology.

What is the market size for an innovation like Kurve’s?

Central nervous system and neurological disorders affect over one billion people worldwide. Each disease state has its own vast market size and dire global need for efficient treatments. The market size for Alzheimer’s treatments is over $12 billion per year. That’s just one of the many diseases we are targeting. Read our blog post to learn more about the Economic Impact of Alzheimer’s Disease.

When is Kurve estimated to be ready for market launch?

We aim to be ready for market launch once we complete our final Phase III clinical trial and compete the registration process with the FDA.

What does your technology mean for the future of neurodegenerative diseases?

Our hope is that our tech-powered CNS disorder treatments will bring much-needed change to the neurodegenerative disease treatment landscape. Kurve’s goal is to eliminate suffering by providing disease-modifying treatments to patients who do not have effective treatment options. While we cannot predict the future, we firmly believe we can make a difference and improve the lives of countless patients.

Is Kurve developing its own drug formulations? Will you partner with pharmaceutical companies?

Yes, we are a medtech and specialty drug product company. We are developing our own patented intranasal insulin and will be developing additional formulations. We encourage pharmaceutical companies to reach out and partner with us. Need and opportunity are abundant for formulation development for the millions of people suffering from neurodegenerative diseases.